Skip to main content
Journal cover image

Long-term oral anticoagulant after catheter ablation for atrial fibrillation.

Publication ,  Journal Article
Chew, D; Piccini, JP
Published in: Europace
August 6, 2021

Catheter ablation is superior to antiarrhythmic therapy for the reduction of symptomatic atrial fibrillation (AF), recurrence, and burden. The possibility of a true 'rhythm' control strategy with catheter ablation has re-opened the debate on rate vs. rhythm control and the subsequent impact on stroke risk. Some observation studies suggest that successful AF catheter ablation and maintenance of sinus rhythm are associated with a decrease in stroke risk, while the CABANA trial had demonstrated no apparent reduction. Other observational studies have demonstrated increased stroke risk when oral anticoagulation (OAC) is discontinued after catheter ablation. When and in whom OAC can be discontinued after ablation will need to be determined in properly conducted randomized control trials. In this review article, we discuss our current understanding of the interactions between AF, stroke, and anticoagulation following catheter ablation. Specifically, we discuss the evidence for the long-term anticoagulation following successful catheter ablation, the potential for OAC discontinuation with restoration of sinus rhythm, and novel approaches to anticoagulation management post-ablation.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Europace

DOI

EISSN

1532-2092

Publication Date

August 6, 2021

Volume

23

Issue

8

Start / End Page

1157 / 1165

Location

England

Related Subject Headings

  • Treatment Outcome
  • Stroke
  • Humans
  • Catheter Ablation
  • Cardiovascular System & Hematology
  • Atrial Fibrillation
  • Anticoagulants
  • Anti-Arrhythmia Agents
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chew, D., & Piccini, J. P. (2021). Long-term oral anticoagulant after catheter ablation for atrial fibrillation. Europace, 23(8), 1157–1165. https://doi.org/10.1093/europace/euaa365
Chew, Derek, and Jonathan P. Piccini. “Long-term oral anticoagulant after catheter ablation for atrial fibrillation.Europace 23, no. 8 (August 6, 2021): 1157–65. https://doi.org/10.1093/europace/euaa365.
Chew D, Piccini JP. Long-term oral anticoagulant after catheter ablation for atrial fibrillation. Europace. 2021 Aug 6;23(8):1157–65.
Chew, Derek, and Jonathan P. Piccini. “Long-term oral anticoagulant after catheter ablation for atrial fibrillation.Europace, vol. 23, no. 8, Aug. 2021, pp. 1157–65. Pubmed, doi:10.1093/europace/euaa365.
Chew D, Piccini JP. Long-term oral anticoagulant after catheter ablation for atrial fibrillation. Europace. 2021 Aug 6;23(8):1157–1165.
Journal cover image

Published In

Europace

DOI

EISSN

1532-2092

Publication Date

August 6, 2021

Volume

23

Issue

8

Start / End Page

1157 / 1165

Location

England

Related Subject Headings

  • Treatment Outcome
  • Stroke
  • Humans
  • Catheter Ablation
  • Cardiovascular System & Hematology
  • Atrial Fibrillation
  • Anticoagulants
  • Anti-Arrhythmia Agents
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology